跳转至内容
Merck
CN
  • Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells.

Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells.

Oncotarget (2017-11-05)
Vijay Pandey, Min Zhang, Qing-Yun Chong, Mingliang You, Ainiah Rushdiana Raquib, Amit K Pandey, Dong-Xu Liu, Liang Liu, Lan Ma, Sudhakar Jha, Zheng-Sheng Wu, Tao Zhu, Peter E Lobie
摘要

Tamoxifen (TAM) is widely used as an adjuvant therapy for women with breast cancer (BC). However, TAM possesses partial oestrogenic activity in the uterus and its use has been associated with an increased incidence of endometrial carcinoma (EC). The molecular mechanism for these observations is not well understood. Herein, we demonstrated that forced expression of

材料
货号
品牌
产品描述

Sigma-Aldrich
MISSION® esiRNA, targeting human TFF3